The forward EV/EBITDA compression from 18.06 to 15.25 implies consensus expects earnings growth to absorb much of the current multiple. Relative to PHG at 12.54x EV/EBITDA and ITGR at 16.96x, ResMed trades near the upper half of the group, which is consistent with its higher-quality margin profile. Investors should monitor whether the forward multiple holds if fiscal Q4 earnings softness proves to be a sustained margin signal rather than a timing effect.

Operating margin has stayed within a 30% to 35% band, which suggests the cost base has flexed with R&D reinvestment without eroding core conversion. The latest quarter's compression in gross and net margin may reflect mix or cost pressure beneath stable demand, and its persistence would be a more meaningful signal than any single quarter. Net margin of 26.2% remains well above the -20.8% to 15.9% range of smaller peers, so the strain is relative rather than structural.

The low ROE relative to margins is largely a function of a large equity base built through retained earnings and a goodwill-heavy asset position, which dilutes asset-level returns. Compared with INSP's 12.5% ROE, ResMed's returns look subdued, though its ROIC compares more favorably against PHG's 6.4% and ITGR's 5.4%. The trend is flat rather than compounding, which warrants monitoring of whether acquisition-driven goodwill is diluting incremental returns.

The decline in D/E reflects debt paydown against a growing equity base, suggesting the balance sheet is de-risking over time. The drop in EBITDA-based coverage to 1.23x in the latest quarter, however, warrants attention even given low absolute debt, as it may reflect lower EBITDA rather than higher interest burden. Refinancing risk appears limited given total debt of roughly $611M against a cash position that has rebuilt substantially.